PURPOSE: It is a critical challenge to determine the risk of recurrence in early stage non-small cell lung cancer (NSCLC) patients. Accurate gene expression signatures are needed to classify patients into high- and low-risk groups to improve the selection of patients for adjuvant therapy. EXPERIMENTAL DESIGN: Multiple published microarray data sets were used to evaluate our previously identified lung cancer prognostic gene signature. Expression of the signature genes was further validated with real-time reverse transcription-PCR and Western blot assays of snap-frozen lung cancer tumor tissues. RESULTS: Our previously identified 35-gene signature stratified 264 patients with NSCLC into high- and low-risk groups with distinct overall survival rates (P < 0.05, Kaplan-Meier analysis, log-rank tests). The 35-gene signature further stratified patients with clinical stage 1A diseases into poor prognostic and good prognostic subgroups (P = 0.0007, Kaplan-Meier analysis, log-rank tests). This signature is independent of other prognostic factors for NSCLC, including age, sex, tumor differentiation, tumor grade, and tumor stage. The expression of the signature genes was validated with real-time reverse transcription-PCR analysis of lung cancer tumor specimens. Protein expression of two signature genes, TAL2 and ILF3, was confirmed in lung adenocarcinoma tumors by using Western blot analysis. These two biomarkers showed correlated mRNA and protein overexpression in lung cancer development and progression. CONCLUSIONS: The results indicate that the identified 35-gene signature is an accurate predictor of survival in NSCLC. It provides independent prognostic information in addition to traditional clinicopathologic criteria.
PURPOSE: It is a critical challenge to determine the risk of recurrence in early stage non-small cell lung cancer (NSCLC) patients. Accurate gene expression signatures are needed to classify patients into high- and low-risk groups to improve the selection of patients for adjuvant therapy. EXPERIMENTAL DESIGN: Multiple published microarray data sets were used to evaluate our previously identified lung cancer prognostic gene signature. Expression of the signature genes was further validated with real-time reverse transcription-PCR and Western blot assays of snap-frozen lung cancer tumor tissues. RESULTS: Our previously identified 35-gene signature stratified 264 patients with NSCLC into high- and low-risk groups with distinct overall survival rates (P < 0.05, Kaplan-Meier analysis, log-rank tests). The 35-gene signature further stratified patients with clinical stage 1A diseases into poor prognostic and good prognostic subgroups (P = 0.0007, Kaplan-Meier analysis, log-rank tests). This signature is independent of other prognostic factors for NSCLC, including age, sex, tumor differentiation, tumor grade, and tumor stage. The expression of the signature genes was validated with real-time reverse transcription-PCR analysis of lung cancer tumor specimens. Protein expression of two signature genes, TAL2 and ILF3, was confirmed in lung adenocarcinoma tumors by using Western blot analysis. These two biomarkers showed correlated mRNA and protein overexpression in lung cancer development and progression. CONCLUSIONS: The results indicate that the identified 35-gene signature is an accurate predictor of survival in NSCLC. It provides independent prognostic information in addition to traditional clinicopathologic criteria.
Authors: Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: Dennis A Wigle; Igor Jurisica; Niki Radulovich; Melania Pintilie; Janet Rossant; Ni Liu; Chao Lu; James Woodgett; Isolde Seiden; Michael Johnston; Shaf Keshavjee; Gail Darling; Timothy Winton; Bobby-Joe Breitkreutz; Paul Jorgenson; Mike Tyers; Frances A Shepherd; Ming Sound Tsao Journal: Cancer Res Date: 2002-06-01 Impact factor: 12.701
Authors: A Bhattacharjee; W G Richards; J Staunton; C Li; S Monti; P Vasa; C Ladd; J Beheshti; R Bueno; M Gillette; M Loda; G Weber; E J Mark; E S Lander; W Wong; B E Johnson; T R Golub; D J Sugarbaker; M Meyerson Journal: Proc Natl Acad Sci U S A Date: 2001-11-13 Impact factor: 11.205
Authors: M E Garber; O G Troyanskaya; K Schluens; S Petersen; Z Thaesler; M Pacyna-Gengelbach; M van de Rijn; G D Rosen; C M Perou; R I Whyte; R B Altman; P O Brown; D Botstein; I Petersen Journal: Proc Natl Acad Sci U S A Date: 2001-11-13 Impact factor: 11.205
Authors: Charles A Powell; Avrum Spira; Adnan Derti; Charles DeLisi; Gang Liu; Alain Borczuk; Steve Busch; Sudhir Sahasrabudhe; Yangde Chen; David Sugarbaker; Raphael Bueno; William G Richards; Jerome S Brody Journal: Am J Respir Cell Mol Biol Date: 2003-02-21 Impact factor: 6.914
Authors: A I Su; J B Welsh; L M Sapinoso; S G Kern; P Dimitrov; H Lapp; P G Schultz; S M Powell; C A Moskaluk; H F Frierson; G M Hampton Journal: Cancer Res Date: 2001-10-15 Impact factor: 12.701
Authors: David G Beer; Sharon L R Kardia; Chiang-Ching Huang; Thomas J Giordano; Albert M Levin; David E Misek; Lin Lin; Guoan Chen; Tarek G Gharib; Dafydd G Thomas; Michelle L Lizyness; Rork Kuick; Satoru Hayasaka; Jeremy M G Taylor; Mark D Iannettoni; Mark B Orringer; Samir Hanash Journal: Nat Med Date: 2002-07-15 Impact factor: 53.440
Authors: Kimberly J Bussey; David Kane; Margot Sunshine; Sudar Narasimhan; Satoshi Nishizuka; William C Reinhold; Barry Zeeberg; Weinstein Ajay; John N Weinstein Journal: Genome Biol Date: 2003-03-25 Impact factor: 13.583
Authors: M Pacurari; Y Qian; D W Porter; M Wolfarth; Y Wan; D Luo; M Ding; V Castranova; N L Guo Journal: Toxicol Appl Pharmacol Date: 2011-05-23 Impact factor: 4.219
Authors: Nancy L Guo; Ying-Wooi Wan; James Denvir; Dale W Porter; Maricica Pacurari; Michael G Wolfarth; Vincent Castranova; Yong Qian Journal: J Toxicol Environ Health A Date: 2012
Authors: Jun Hou; Joachim Aerts; Bianca den Hamer; Wilfred van Ijcken; Michael den Bakker; Peter Riegman; Cor van der Leest; Peter van der Spek; John A Foekens; Henk C Hoogsteden; Frank Grosveld; Sjaak Philipsen Journal: PLoS One Date: 2010-04-22 Impact factor: 3.240